UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Surgery Versus Chemotherapy and Radiotherapy For Early and Locally Advanced Small Cell Lung Cancer: A Propensity-Matched Analysis of Survival

Lung cancer (Amsterdam, Netherlands), 2017-07, Vol.109, p.78-88

2017

Volltextzugriff (PDF)

Trends, practice patterns and underuse of surgery in the treatment of early stage small cell lung cancer

Lung cancer (Amsterdam, Netherlands), 2017-07, Vol.109, p.117-123

2017

Volltextzugriff (PDF)

Consensus recommendations for optimizing biomarker testing to identify and treat advanced EGFR- mutated non-small-cell lung cancer

Current oncology (Toronto), 2020-12, Vol.27 (6), p.321-329

2020

Volltextzugriff (PDF)

Management of egfr tki-induced dermatologic adverse events

Current oncology (Toronto), 2015-04, Vol.22 (2), p.123-132

2015

Volltextzugriff (PDF)

Afatinib in advanced pretreated non-small-cell lung cancer- a Canadian experience

Current oncology (Toronto), 2018-10, Vol.25 (5), p.e385-390

2018

Volltextzugriff (PDF)

A population-based study of the epidemiology of pancreatic cancer: a brief report

Current oncology (Toronto), 2015-12, Vol.22 (6), p.e478-484

2015

Volltextzugriff (PDF)

Biomarker testing and time to treatment decision in patients with advanced nonsmall-cell lung cancer

Annals of oncology, 2015-07, Vol.26 (7), p.1415-1421

2015

Volltextzugriff (PDF)

Safety and Clinical Activity of MK-3475 as Initial Therapy in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

International journal of radiation oncology, biology, physics, 2014-11, Vol.90 (5), p.S1-S2

2014

Volltextzugriff (PDF)

42 10 year retrospective review of single agent chemotherapy as first line treatment in advanced non-small cell lung cancer (NSCLC) in Princess Margaret Hospital: Assessment of efficacy and prognostic factors

Lung cancer (Amsterdam, Netherlands), 2013, Vol.79, p.S14-S15

2013

Volltextzugriff (PDF)

Treatment paradigms for patients with metastatic non-small-cell lung cancer: first-, second-, and third-line

Current oncology (Toronto), 2012-06, Vol.19 (Suppl 1), p.S52-58

Leighl, N B

2012

Volltextzugriff (PDF)

607 NCIC CTG IND.196: Phase I Study of Foretinib (GSK1363089) and Erlotinib in Patients with Advanced Pretreated NSCLC

European journal of cancer (1990), 2012-11, Vol.48, p.187-187

2012

Volltextzugriff (PDF)

Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial

Annals of oncology, 2017-04, Vol.28 (4), p.874-881

2017

Volltextzugriff (PDF)

127 Correlation of clinical activity of pembrolizumab (MK-3475) with immunohistochemical staining for programmed death-1 ligand (PD-L1) in ≥50% of tumor cells in a prospective non-small cell lung cancer (NSCLC) validation population

European journal of cancer (1990), 2014-11, Vol.50, p.44-45

2014

Volltextzugriff (PDF)

Clinical definition of acquired resistance to immunotherapy in patients with metastatic non-small-cell lung cancer

Annals of oncology, 2021-12, Vol.32 (12), p.1597-1607

2021

Volltextzugriff (PDF)

1287P Predictive value of weight and BSA in assessing toxicity during ALK-TKIs in non-small cell lung cancer

Annals of oncology, 2024-09, Vol.35, p.S820-S820

2024

Volltextzugriff (PDF)

Delayed immune-related adverse events in assessment for dose-limiting toxicity in early phase immunotherapy trials

European journal of cancer (1990), 2019-01, Vol.107, p.1-7

2019

Volltextzugriff (PDF)

P31 The impact of a Comprehensive Geriatric Assessment (CGA) on medical oncology treatment decisions for elderly patients with cancer

Critical reviews in oncology/hematology, 2009, Vol.72 (1), p.S29-S30

2009

Volltextzugriff (PDF)

PPM4 Health and Budget IMPACT of Liquid-Based Comprehensive Genomic Profile Testing (CGP) in Advance NON-SMALL CELL LUNG Cancer (ANSCLC) Patients with Insufficient Tissue, Exhausted Tissue Samples and or Insufficient DNA in Tissue Samples

Value in health, 2020-12, Vol.23, p.S687-S687

2020

Volltextzugriff (PDF)

1304P Investigator-initiated study of crizotinib in patients with MET activated advanced stage non-small cell lung cancer: A Canadian experience

Annals of oncology, 2024-09, Vol.35, p.S829-S830

2024

Volltextzugriff (PDF)

Outcomes of Bimodality and Trimodality Therapy in Patients with Stage III Non-small Cell Lung Cancer (NSCLC)

International journal of radiation oncology, biology, physics, 2010, Vol.78 (3), p.S505-S505

2010

Volltextzugriff (PDF)

P2.10A.07 Trofuse-009: Phase 3 Study of Sac-TNT vs Platinum-Doublet Chemotherapy for Previously Treated EGFR-Mutated Advanced NSCLC

Journal of thoracic oncology, 2024-10, Vol.19 (10), p.S246-S247

2024

Volltextzugriff (PDF)

HTA4 Pembrolizumab Vs. Standard of Care Chemotherapy As First-Line Treatment for Advanced Non-Small Cell Lung Cancer with High Pd-L1 Expression Levels: A Cost-Utility Analysis from the Ontario, Canada Public Payer Perspective

Value in health, 2023-06, Vol.26 (6), p.S259-S259

2023

Volltextzugriff (PDF)

1236P ctDNA-Lung-Detect: Profiling of non-shedding ctDNA early stage resected non-small cell lung cancers

Annals of oncology, 2024-09, Vol.35, p.S792-S792

2024

Volltextzugriff (PDF)

1362P Evaluation of imaging-based prognostication (IPRO) for advanced non-small cell lung cancer (aNSCLC) using deep learning applied to computed tomography (CT)

Annals of oncology, 2024-09, Vol.35, p.S858-S858

2024

Volltextzugriff (PDF)

P2.09-28 Effect of TP53 Variants in HER2-mutated Non-Small Cell Lung Cancer (NSCLC)

Journal of thoracic oncology, 2023-11, Vol.18 (11), p.S343-S344

2023

Volltextzugriff (PDF)

1 – 25 von 87

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(87)
Mit Volltextzugriff
(87)

Publikationsform

Artikel
(87)

Sprache

Englisch
(87)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(34)
Oncology
(34)
Science & Technology
(34)
Original
(14)
Humans
(12)
Hematology, Oncology And Palliative Medicine
(8)
Lung Neoplasms - Drug Therapy
(8)
Non-Small-Cell Lung Cancer
(8)
Nsclc
(8)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(7)
Female
(7)
Breast Cancer
(6)
Male
(6)
Aged
(5)
Lung Cancer
(5)
Middle Aged
(5)
Adult
(4)
Aged, 80 And Over
(4)
Immunotherapy
(4)
Advanced
(3)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

2 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(12)

Menü

Weitere Dienste

Einstellungen

Surgery Versus Chemotherapy and Radiotherapy For Early and Locally Advanced Small Cell Lung Cancer: A Propensity-Matched Analysis of Survival

Trends, practice patterns and underuse of surgery in the treatment of early stage small cell lung cancer

Consensus recommendations for optimizing biomarker testing to identify and treat advanced EGFR- mutated non-small-cell lung cancer

Management of egfr tki-induced dermatologic adverse events

Afatinib in advanced pretreated non-small-cell lung cancer- a Canadian experience

A population-based study of the epidemiology of pancreatic cancer: a brief report

Biomarker testing and time to treatment decision in patients with advanced nonsmall-cell lung cancer

Safety and Clinical Activity of MK-3475 as Initial Therapy in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

42 10 year retrospective review of single agent chemotherapy as first line treatment in advanced non-small cell lung cancer (NSCLC) in Princess Margaret Hospital: Assessment of efficacy and prognostic factors

Treatment paradigms for patients with metastatic non-small-cell lung cancer: first-, second-, and third-line

607 NCIC CTG IND.196: Phase I Study of Foretinib (GSK1363089) and Erlotinib in Patients with Advanced Pretreated NSCLC

Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial

127 Correlation of clinical activity of pembrolizumab (MK-3475) with immunohistochemical staining for programmed death-1 ligand (PD-L1) in ≥50% of tumor cells in a prospective non-small cell lung cancer (NSCLC) validation population

Clinical definition of acquired resistance to immunotherapy in patients with metastatic non-small-cell lung cancer

1287P Predictive value of weight and BSA in assessing toxicity during ALK-TKIs in non-small cell lung cancer

Delayed immune-related adverse events in assessment for dose-limiting toxicity in early phase immunotherapy trials

P31 The impact of a Comprehensive Geriatric Assessment (CGA) on medical oncology treatment decisions for elderly patients with cancer

PPM4 Health and Budget IMPACT of Liquid-Based Comprehensive Genomic Profile Testing (CGP) in Advance NON-SMALL CELL LUNG Cancer (ANSCLC) Patients with Insufficient Tissue, Exhausted Tissue Samples and or Insufficient DNA in Tissue Samples

1304P Investigator-initiated study of crizotinib in patients with MET activated advanced stage non-small cell lung cancer: A Canadian experience

Outcomes of Bimodality and Trimodality Therapy in Patients with Stage III Non-small Cell Lung Cancer (NSCLC)

P2.10A.07 Trofuse-009: Phase 3 Study of Sac-TNT vs Platinum-Doublet Chemotherapy for Previously Treated EGFR-Mutated Advanced NSCLC

HTA4 Pembrolizumab Vs. Standard of Care Chemotherapy As First-Line Treatment for Advanced Non-Small Cell Lung Cancer with High Pd-L1 Expression Levels: A Cost-Utility Analysis from the Ontario, Canada Public Payer Perspective

1236P ctDNA-Lung-Detect: Profiling of non-shedding ctDNA early stage resected non-small cell lung cancers

1362P Evaluation of imaging-based prognostication (IPRO) for advanced non-small cell lung cancer (aNSCLC) using deep learning applied to computed tomography (CT)

P2.09-28 Effect of TP53 Variants in HER2-mutated Non-Small Cell Lung Cancer (NSCLC)

Suchergebnisse filtern